1 result

• MoneyWeight-loss drugs are becoming a snack-company problem.PepsiCo is already fighting inflation, weak snack volumes and investor pressure. GLP-1 drugs add a more structural question: what happens to a food business built around frequent snacking when some customers feel less hungry?